Checkpoint Therapeutics, Inc.
DelistedCIK 1651407fmd_0ABNVE7SFRFFQ934W90DC8VYSXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Mar 31, 2025, 41 periods
Latest annual · FY2024
Millions- Total revenues
- 0
- Operating income
- (56)
- Net income
- (56)
Latest quarter · Q4 FY2024
Millions- Total revenues
- 0
- Operating income
- (11)
- Net income
- (11)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2021 to FY2024
- n/m
- Revenue, 5 yearsFY2019 to FY2024
- n/m
- Net income, 5 yearsFY2019 to FY2024
- n/m
Checkpoint Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Revenue | $41,000 | $103,000 | -60.2% | 10-K 2025-03-28 · proof |
| Operating income | -$56.2 million | -$52.1 million | 10-K 2025-03-28 · proof | |
| Net income | -$56.2 million | -$51.8 million | 10-K 2025-03-28 · proof | |
| Cash from operating activities | -$31.1 million | -$47.6 million | 10-K 2025-03-28 · proof | |
| Total assets | $7.5 million | $5.4 million | +38.9% | 10-K 2025-03-28 · proof |
| Total liabilities | $20.1 million | $18.4 million | +9.1% | 10-K 2025-03-28 · proof |
| Cash and cash equivalents | $6.6 million | $4.9 million | +34% | 10-K 2025-03-28 · proof |
- What was Checkpoint Therapeutics, Inc.'s revenue in fiscal 2024?
- Checkpoint Therapeutics, Inc. reported revenue of $41,000 for fiscal 2024 (the year ended Dec 31, 2024), against $103,000 the year before (-60.2%). Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What was Checkpoint Therapeutics, Inc.'s operating income in fiscal 2024?
- Checkpoint Therapeutics, Inc. reported operating income of -$56.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$52.1 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What was Checkpoint Therapeutics, Inc.'s net income in fiscal 2024?
- Checkpoint Therapeutics, Inc. reported net income of -$56.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$51.8 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What was Checkpoint Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
- Checkpoint Therapeutics, Inc. reported cash from operating activities of -$31.1 million for fiscal 2024 (the year ended Dec 31, 2024), against -$47.6 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What are Checkpoint Therapeutics, Inc.'s total assets?
- As of Dec 31, 2024, Checkpoint Therapeutics, Inc. reported total assets of $7.5 million, against $5.4 million a year earlier (+38.9%). Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What are Checkpoint Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2024, Checkpoint Therapeutics, Inc. reported total liabilities of $20.1 million, against $18.4 million a year earlier (+9.1%). Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
- What are Checkpoint Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Checkpoint Therapeutics, Inc. reported cash and cash equivalents of $6.6 million, against $4.9 million a year earlier (+34%). Source: the 10-K filed with the SEC on Mar 28, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1651407&period_type=annual&limit=5"Information only, not investment advice.